WASHINGTON, April 9 (Reuters) - Biopharmaceutical company Orexigen Therapeutics on Monday said it is planning an initial public offering of 6 million shares for between $11 and $13 per share.
WASHINGTON, April 9 (Reuters) - Biopharmaceutical company Orexigen Therapeutics on Monday said it is planning an initial public offering of 6 million shares for between $11 and $13 per share.